Phase 2
N=70
RNS® System Feasibility Study
Epilepsy
Bottom Line
View on ClinicalTrials.gov: NCT00079781 ↗Enrolled (actual)
70
Serious AEs
44.6%
Results posted
Dec 2013
Primary outcome: Primary: Acute SAE Rate — 6.2 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- RNS® System implantation (Procedure); RNS® System responsive stimulation (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NeuroPace
- Primary completion
- May 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acute SAE Rate |
6.2 | — |
| PRIMARY Short-term Chronic SAE Rate |
9.2 | — |
| PRIMARY Responder Rate |
24 | — |
Summary
The RNS® System is intended to treat patients with medically refractory (hard to treat) epilepsy. The RNS® System Feasibility study is designed to demonstrate safety and evidence of effectiveness of the RNS® System to support the commencement of a pivotal clinical investigation.
Eligibility Criteria
Inclusion Criteria
- Subject has simple partial seizures (motor or sensory) or complex partial seizures (with motor manifestations) with or without secondarily generalized seizures
- Subject has seizures that are distinct, stereotypical events that can be reliably counted, in the opinion of the investigator, by the subject or caregiver
- Subject has seizures that are severe enough to cause injuries or significantly impair functional ability in domains including employment, psychosocial, education and mobility
- Subject failed treatment with a minimum of two antiseizure medications (used in appropriate doses) with adequate monitoring of compliance and the effects of treatment
- Subject has remained on the same antiseizure medication(s) over the preceding three (3) months (independent of dose and other than acute, intermittent use of benzodiazepines)
- Subject has a minimum of four (4) or more countable seizures every month over the last three (3) months, as reported from the NeuroPace sponsored Prospective Seizure Frequency Clinical Investigation
- Subject is ≥ 18 years old and ≤ 65 years old
- Subject has undergone diagnostic testing that has established the epileptiform activity onset region(s) as part of his/her standard care to determine candidacy for epilepsy surgery
- Subject is male, or if female is using a reliable method of contraception (hormonal, barrier method, surgical or abstention), or is at least two years postmenopause
- Subject or legal guardian is able to provide appropriate consent to participate
- Subject can be reasonably expected to maintain a seizure diary alone or with the assistance of a competent individual
- Subject is able to complete regular office visits and telephone appointments per the protocol requirements
- Subject is willing to be implanted with the RNS® System as a treatment for his/her seizures
- Subject is able to tolerate a neurosurgical procedure
- Subject is considered a good candidate to be implanted with an RNS® System
Note: 1 month = 28 days
Exclusion Criteria
- Subject has been diagnosed with psychogenic or non-epileptic seizures in the preceding year
- Subject has been diagnosed with primarily generalized seizures
- Subject has experienced unprovoked status epilepticus in the preceding year
- In the opinion of the investigator, the subject has a clinically significant or unstable medical condition or a progressive central nervous system disease
- Subject has been diagnosed with active psychosis, severe depression or suicidal ideation in the preceding year
- Subject is pregnant or planning on becoming pregnant in the next year
- Subject is on the ketogenic diet
- Subject was enrolled in a therapeutic investigational drug or device study in the preceding year
- Subject has an implanted Vagus Nerve Stimulator (VNS)
- Subject has had therapeutic surgery to treat epilepsy in the preceding year
- Subject is implanted with an electronic medical device that delivers electrical energy to the head or body
- Subject is on chronic anticoagulants or, in the opinion of the investigator, subject is an unsuitable candidate for cranial surgery for any other reason
- Subject had a cranial neurosurgical procedure in the previous month
- Subject requires repeat MRIs
- Subject's seizure onset zone(s) is/are located below the level of the subthalamic nucleus or, in the opinion of the investigator, the necessary lead placement would present too high a risk
Note: Subjects with an inactive VNS could be enrolled so long as the VNS was explanted prior to or at the same time as the RNS® System implant. Subjects who had had epilepsy surgery (resective, corpus callosotomy or ablation) greater than one year ago were still eligible.
Data sourced from ClinicalTrials.gov (NCT00079781). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.